
Quarterly report 2025-Q3
added 11-13-2025
Neoleukin Therapeutics Financial Statements 2011-2025 | NLTX
Annual Financial Statements Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.72 M | 37.6 M | 142 M | 682 M | 318 M | 52.7 M | 305 M | 333 M | 133 M | 92 M | - | - | - |
Shares |
492 K | 55.2 M | 55 M | 54.1 M | 27 M | 23.5 M | 23.5 M | 18.9 M | 12.6 M | 8.67 M | - | - | - |
Historical Prices |
3.49 | 0.68 | 2.58 | 12 | 9.7 | 2.64 | 14.5 | 17.3 | 8.89 | 9.75 | - | - | - |
Net Income |
13.7 M | -55.2 M | -60.7 M | -33.3 M | -69.4 M | -31.6 M | -50.2 M | -37 M | -21.9 M | -24 M | -8.73 M | -7.71 M | - |
Revenue |
- | - | - | - | - | 25 M | - | - | - | - | - | - | - |
Operating Income |
-55.6 M | -56.5 M | -60.7 M | -33.7 M | -71 M | -32.6 M | -51.1 M | -37.6 M | - | - | - | - | - |
Interest Expense |
12 K | 2 K | 19 K | -44 K | 1 K | 4 K | 4 K | 1 K | -520 K | 462 K | 42.9 K | 9.47 K | - |
EBITDA |
-52.3 M | -53.3 M | -59.4 M | -47.6 M | -22.9 M | -31.5 M | -50.2 M | -37.1 M | -21.7 M | -22.2 M | -9.68 M | -7.53 M | - |
Operating Expenses |
55.6 M | 56.5 M | 60.7 M | 41.6 M | 23.2 M | 57.6 M | 51.1 M | 37.6 M | 21.3 M | 22.4 M | - | - | - |
General and Administrative Expenses |
11.2 M | 9.01 M | 21.5 M | 17.2 M | 18.8 M | 15.8 M | 14.9 M | 9.26 M | 5.54 M | 4.3 M | 1.78 M | 1.64 M | - |
All numbers in USD currency
Quarterly Income Statement Neoleukin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
21.2 M | 21.1 M | 21 M | 14.9 M | 17 M | 16.9 M | 16.9 M | 12.8 M | 446 K | 444 K | 55.4 M | 8.53 M | 11.1 M | 55.2 M | 55.1 M | 42.5 M | 55.1 M | 55 M | 54.9 M | 42.2 M | 54.1 M | 49.4 M | 49.2 M | 38 M | 26.2 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 23.4 M | 23.4 B | 23.4 M | 17.7 M | 17.2 M | 17.2 M | 17.2 M | 11.8 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 3.15 M | 302 K | 302 K | 302 K | 302 K | - | - | - | - | - | - | - | - |
Net Income |
-21 M | -22 M | -22.6 M | - | -20.2 M | -18.5 M | -16.9 M | - | -14.6 M | -11.9 M | -14.2 M | - | -13.1 M | -15.7 M | -15.4 M | - | -15.4 M | -15.1 M | -15 M | - | -2.25 M | -9.75 M | -8.64 M | - | -59.1 M | -1 K | -2.21 M | - | -15 M | 2.92 M | -14.6 M | - | -11.8 M | -13.8 M | -8.32 M | - | -8.15 M | -10.9 M | -6.71 M | - | -5.04 M | -4.75 M | -6.41 M | - | -6.28 M | -5.42 M | -4.23 M | - | -3.37 M | -812 K | -1.01 M | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | 925 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25 M | 25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-23.8 M | -26.1 M | -25.9 M | - | -22.2 M | -20.1 M | -18.8 M | - | -15.2 M | -12.6 M | -15.1 M | - | -13.6 M | -15.9 M | -15.4 M | - | -15.5 M | -15.1 M | -14.9 M | - | -2.25 M | -9.77 M | -9.07 M | - | -59.5 M | -428 K | - | - | -15.2 M | 2.69 M | - | - | -12.1 M | -14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | 1.04 M | 981 K | 945 K | - | 559 K | 194 K | 13 K | - | 6 K | - | - | - | - | - | - | - | -9 K | - | -1 K | - | -262 K | -118 K | -53 K | - | -7 K | -9 K | -20 K | - | -12 K | 164 K | 123 K | - | 4 K | 5 K | 6 K | - | 2 K | 2 K | 454 K | - | 1.64 K | 1.77 K | 1.83 K | - | - | - | - | - | - | - | - |
EBITDA |
-23 M | -25.3 M | -25.2 M | - | -21.4 M | -19.3 M | -18 M | - | -14.4 M | -11.8 M | -14.8 M | - | -12.4 M | -15 M | -15 M | - | -14.5 M | -14.6 M | -14.7 M | - | -1.67 M | -9.38 M | -8.9 M | - | -59.3 M | -346 K | 41 K | - | -15.2 M | 2.69 M | - | - | -12.1 M | -14 M | - | - | - | - | - | - | - | - | - | - | - | 71.9 K | 18.2 K | - | 45.2 K | 15.6 K | 14.8 K | - | - | - | - | - | - | - | - |
Operating Expenses |
23.8 M | 26.1 M | 25.9 M | - | 22.2 M | 21.1 M | 18.8 M | - | 15.2 M | 12.6 M | 15.1 M | - | 13.6 M | 15.9 M | 15.4 M | - | 15.5 M | 15.1 M | - | - | - | 9.77 M | 9.07 M | - | 59.5 M | 428 K | 2.66 M | - | 15.2 M | 22.3 M | 14.8 M | - | 12.1 M | 14 M | 8.52 M | - | 8.28 M | 11.1 M | 6.83 M | - | 4.92 M | 4.79 M | 6.04 M | - | 6.31 M | 5.63 M | 2.62 M | - | 3.42 M | 1.62 M | 997 K | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
6.56 M | 6.72 M | 8.16 M | - | 5.9 M | 5.32 M | 5.24 M | - | 3.61 M | 2.28 M | 4.03 M | - | 4.14 M | 4.92 M | 4.66 M | - | 5.56 M | 5.3 M | 5.24 M | - | 3.86 M | 4.93 M | 3.57 M | - | 10.4 M | 2.42 M | 2.56 M | - | 4.48 M | 4.31 M | 4.31 M | - | 3.61 M | 3.52 M | 2.74 M | - | 2.15 M | 1.83 M | 1.95 M | - | 1.23 M | 1.17 M | 1.47 M | - | 987 K | 1.08 M | 735 K | - | 390 K | 370 K | 424 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements Neoleukin Therapeutics NLTXFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Neoleukin Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
$ 1.7 | 50.0 % | $ 183 M | ||
|
Cronos Group
CRON
|
$ 3.24 | 13.51 % | $ 1.69 B | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | ||
|
Harrow Health
HROW
|
$ 47.18 | -7.67 % | $ 1.54 B | ||
|
Aurora Cannabis
ACB
|
$ 5.36 | 17.8 % | $ 86.3 M | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | ||
|
Emergent BioSolutions
EBS
|
$ 11.46 | -2.22 % | $ 587 M | ||
|
Evoke Pharma
EVOK
|
$ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.38 | -0.05 % | $ 2.03 B | ||
|
Pacira BioSciences
PCRX
|
$ 26.28 | 2.14 % | $ 1.22 B | ||
|
Evolus
EOLS
|
$ 6.99 | 1.09 % | $ 433 M | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | ||
|
China Pharma Holdings
CPHI
|
$ 1.67 | 11.33 % | $ 29.2 M | ||
|
Perrigo Company plc
PRGO
|
$ 13.13 | -2.23 % | $ 1.8 B | ||
|
ProPhase Labs
PRPH
|
$ 0.12 | -15.26 % | $ 1.9 M | ||
|
Rockwell Medical
RMTI
|
$ 0.93 | -2.37 % | $ 21.7 M | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | ||
|
Bausch Health Companies
BHC
|
$ 6.95 | -0.93 % | $ 2.54 B | ||
|
SCYNEXIS
SCYX
|
$ 0.64 | -0.02 % | $ 30.6 M | ||
|
Assertio Holdings
ASRT
|
$ 0.77 | -1.79 % | $ 54.7 M | ||
|
OrganiGram Holdings
OGI
|
$ 1.88 | 14.72 % | $ 402 M | ||
|
Solid Biosciences
SLDB
|
$ 5.85 | -0.34 % | $ 239 M | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | ||
|
Organogenesis Holdings
ORGO
|
$ 4.83 | 1.15 % | $ 636 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.59 | -3.37 % | $ 4.46 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 2.61 | 4.99 % | $ 36.7 M | ||
|
Relmada Therapeutics
RLMD
|
$ 4.12 | -1.67 % | $ 124 M | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | ||
|
Sundial Growers
SNDL
|
$ 2.19 | 24.01 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | ||
|
Veru
VERU
|
$ 2.45 | -4.3 % | $ 330 M | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | ||
|
cbdMD
YCBD
|
$ 1.18 | 87.31 % | $ 5.09 M | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | ||
|
Tilray
TLRY
|
$ 11.86 | 40.68 % | $ 7.33 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | ||
|
TherapeuticsMD
TXMD
|
$ 1.79 | -2.72 % | $ 18.7 M |